FDA approves orforglipron (Foundayo), a GLP-1 pill without food or water rules
The FDA approved Eli Lilly’s orforglipron for adults with obesity, or overweight with a weight-related condition, after a 50-day review under a new priority program. In ATTAIN-1, the 36 mg dose produced a mean 11.2% weight loss at 72 weeks versus 2.1% on placebo.
EVIDENCE
Regulatory decision
WHY IT MATTERS
A small-molecule pill that can be taken any time of day could widen access, although average weight loss is lower than with the strongest injections.
The details
Unlike peptide pills, orforglipron does not need to be taken on an empty stomach with a fixed wait before eating. Participants also improved waist circumference, blood pressure, triglycerides and cholesterol.
Gastrointestinal side effects led 5–10% of trial participants to stop treatment, compared with about 3% on placebo.
Educational summary only. It is not medical advice and does not replace a conversation with your clinician.